GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease.

about

Hypoglycemic agents and potential anti-inflammatory activity Diabetes and Hepatitis C: A Two-Way Association.Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview.A systematic review of the present and future of non-alcoholic fatty liver disease

P2860

Q26750414-51B5F6C3-AC88-4E05-A709-3714BE440AA9 Q36056076-1D16F211-036B-4AD1-9D61-32AD2BC8457E Q38782562-ADB955B4-6084-48B3-B83B-993AF1C3F3DF Q57494349-DD80996B-E026-4D43-9BEB-FA8F973FEC54

P2860

GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease.

Item

http://www.wikidata.org/entity/Q38234416

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease.

@en

type

Item

label

GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease.

@en

prefLabel

GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease.

@en

P1476

GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease.

@en

P2093

Guang Wang

http://www.w3.org/2001/XMLSchema#string

Jia Liu

http://www.w3.org/2001/XMLSchema#string

Yuan Xu

http://www.w3.org/2001/XMLSchema#string

Yumei Jia

http://www.w3.org/2001/XMLSchema#string

P2860

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

Insulin signalling and the regulation of glucose and lipid metabolism

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH)

Obesity is associated with macrophage accumulation in adipose tissue

The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

Steatohepatitis: a tale of two "hits"?

Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

Adipokines in inflammation and metabolic disease

P304

329-335

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/DMRR.2580

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264288430

http://www.w3.org/2001/XMLSchema#string

P698

25066109

http://www.w3.org/2001/XMLSchema#string

GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease.

about

P2860

P2860

GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698